Latest Regulatory Approvals News

PointsBet has secured a significantly improved acquisition proposal from MIXI, lifting the cash offer by 13.2% to $1.20 per share and postponing the shareholder vote to June 25. The move intensifies the takeover battle amid ongoing regulatory approvals and a rival bid from Betr Entertainment.

Asra Minerals Limited has launched a substantial options offer linked to a recent $3 million placement, aiming to enhance liquidity and satisfy obligations under the placement. The company plans to list these options on the ASX by the end of June 2025.

Manuka Resources is poised to restart silver production at its Wonawinta Mine targeting 13.2 million ounces, while progressing its large-scale vanadium-titanium-magnetite project in New Zealand with a robust $1.26 billion valuation.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

Western Yilgarn NL has secured the Cardea 3 Bauxite Project in Western Australia's Darling Range, adding a significant high-grade bauxite asset near its Julimar Project. Historical drilling confirms strong alumina grades and strategic infrastructure access.

Titanium Sands Limited has locked in a $600,000 convertible loan facility from major shareholders to fund environmental studies and progress its Mannar Heavy Mineral Project. This funding milestone follows recent regulatory approvals and marks a critical step forward for the company.

Paradigm Biopharmaceuticals has reached key milestones in its global Phase 3 trial for knee osteoarthritis, activating its first Australian clinical site and enrolling the first patient. With multiple sites in Australia and the US preparing for recruitment, the trial is advancing steadily toward critical data readouts.

EMVision Medical Devices has activated two additional key sites in its pivotal trial for the emu™ bedside brain scanner, advancing its path toward FDA clearance. These new sites join a growing network of leading stroke centres across the US and Australia.

James Hardie Industries has successfully syndicated $3.5 billion in new credit facilities, providing robust financial backing for its planned merger with The AZEK Company Inc. This move significantly reduces prior bridge loan commitments and enhances the company’s financial flexibility.

Cardiex Limited has gained Therapeutic Goods Administration approval for its CONNEQT Pulse device, paving the way for commercial expansion in Australia alongside its established US presence.

EV Resources Limited has agreed to sell its Yanamina Gold and Silver Project in Peru to Daura Gold Corp for US$6 million, a move that will bolster EVR’s cash reserves and sharpen its strategic focus.

Neurotech International has reported positive human pharmacokinetic results for NTI164, a cannabinoid formulation designed for paediatric neurological disorders, confirming rapid absorption and a non-intoxicating profile.